A Comparison of Endoscopic Synchronous Injection and Submucosal Dissection(ESISD) and Conventiona… (NCT07236827) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
A Comparison of Endoscopic Synchronous Injection and Submucosal Dissection(ESISD) and Conventional Endoscopic Submucosal Dissection(CESD) for Granular Mixed Nodular Laterally Spreading Tumor in the Rectum (LST-G-M)
60 participantsStarted 2025-12-01
Plain-language summary
What is the study about? This study introduces and evaluates a new endoscopic technique called Endoscopic Synchronized Injection and Submucosal Dissection (ESISD). It is designed to remove large, flat precancerous growths in the rectum, known as Granular Mixed Nodular Laterally Spreading Tumors (LST-G-M). We compared this new technique to the standard procedure, Conventional Endoscopic Submucosal Dissection (ESD), to see if it is safer, faster, and more efficient.
Who is this for? This research is intended for patients with large, flat rectal polyps, their families seeking the latest treatment options, and healthcare providers interested in advancements in minimally invasive gastroenterology procedures.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age ≥ 18 years.
✓. Endoscopic diagnosis of a large (≥ 20 mm) granular mixed nodular laterally spreading tumor (LST-G-M) located in the rectum.
✓. Lesion situated 0-15 cm from the anal verge.
✓. Pre-procedure imaging (e.g., EUS) and endoscopic assessment suggest a very low to low risk of lymph node metastasis (i.e., lesions confined to the mucosa or with superficial submucosal invasion \< 1000 μm).
✓. Deemed suitable for Endoscopic Submucosal Dissection (ESD) based on a comprehensive clinical evaluation by the endoscopist.
✓. Provision of signed and dated informed consent form.
Exclusion criteria
✕. Coagulopathy that cannot be adequately corrected, including an international normalized ratio (INR) \> 1.5 or a platelet count \< 50,000/μL.
✕. Evidence of deep submucosal invasion (≥ 1000 μm) or obvious non-lifting sign, suggesting a need for surgical intervention.
✕
What they're measuring
1
procedure time
Timeframe: From enrollment to the end of treatment at 1 day
2
Hospitalization cost
Timeframe: From enrollment to the end of treatment at 10 days